Challenges for HCV vaccine development in HIV-HCV coinfection

Expert Review of Vaccines

Volumn 11, Issue 7, 2012, Pages 791-804

  Lambotin, Mélanie ^a,b   Barth, Heidi ^a,b,c   Moog, Christiane ^a,b   Habersetzer, François ^a,b,c   Baumert, Thomas F ^a,b,c   Stoll Keller, Françoise ^a,b,c   Fafi Kremer, Samira ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

coinfection; HCV; HIV; treatment; vaccine

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BOCEPREVIR; CYTOCHROME P450; HEPATITIS C VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RIBAVIRIN; TELAPREVIR;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DELTA AGENT HEPATITIS; DISEASE COURSE; FIBROSIS; HEALTH CARE; HEPATITIS A; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LEUKOPENIA; META ANALYSIS (TOPIC); MIXED INFECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SACCHAROMYCES CEREVISIAE; SEXUAL TRANSMISSION; SYPHILIS; TREATMENT OUTCOME; VIREMIA;

ANIMALS; COINFECTION; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME; VACCINATION; VIRAL HEPATITIS VACCINES;

EID: 84865417045     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.52     Document Type: Review

References (132)

1. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J. Hepatol. 44(Suppl. 1), S6-S9 (2006). (Pubitemid 43053865)
2. Kim AY, Chung RT. Coinfection with HIV-1 and HCV-a one-two punch. Gastroenterology 137(3), 795-814 (2009).An excellent review on what is known about HIV and HCV interaction with their respective host immune responses in coinfected individuals.
3. Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J. Hepatol. 56(Suppl. 1), S88-100 (2012). An excellent overview of novel combination therapies in patients infected with HCV genotype 1 and recent clinical results with new drugs development.
4. Deming P, McNicholl IR. Coinfection with human immunodeficiency virus and hepatitis C virus: Challenges and therapeutic advances. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 31(4), 357-368 (2011).
5. Thomas DL. The challenge of hepatitis C in the HIV-infected person. Annu. Rev. Med. 59, 473-485 (2008). (Pubitemid 351287950)
6. Carrat F, Bani-Sadr F, Pol S et al.; ANRS HCO2 RIBAVIC Study Team. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial. JAMA 292(23), 2839-2848 (2004). (Pubitemid 39628231)
7. Chung RT, Andersen J, Volberding P et al.; AIDS Clinical Trials Group A5071 Study Team. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N. Engl. J. Med. 351(5), 451-459 (2004). (Pubitemid 38988594)
8. Loko MA, Salmon D, Carrieri P et al.; ANRS CO 13 HEPAVIH Study Group. The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): Early findings, 2006-2010. BMC Infect. Dis. 10, 303 (2010).
9. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al.; APRICOT Study Group. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med. 351(5), 438-450 (2004). (Pubitemid 38988593)
10. Cacoub P, Halfon P, Rosenthal E et al. Care of hepatitis C virus infection in human immunodeficiency virus-infected patients: Modifications in three consecutive large surveys between 2004 and 2009. J. Hepatol. 53(2), 230-237 (2010).
11. Williams IT, Bell BP, Kuhnert W, Alter MJ. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Arch. Intern. Med. 171(3), 242-248 (2011).
12. Giraudon I, Ruf M, Maguire H et al. Increase in diagnosed newly acquired hepatitis C in HIV-positive men who have sex with men across London and Brighton, 2002-2006: Is this an outbreak? Sex. Transm. Infect. 84(2), 111-115 (2008). (Pubitemid 351497921)
13. Urbanus AT, van Houdt R, van de Laar TJ, Coutinho RA. Viral hepatitis among men who have sex with men, epidemiology and public health consequences. Euro Surveill. 14(47), pii: 19421 (2009).
14. Van De Laar Tj, Van Der Bij Ak, Prins M et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J. Infect Dis. 196(2), 230-238 (2007). (Pubitemid 47047462)
15. Rauch A, Rickenbach M, Weber R et al.; Swiss HIV Cohort Study. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: The Swiss HIV Cohort Study. Clin. Infect. Dis. 41(3), 395-402 (2005). (Pubitemid 41022120)
16. Gambotti L, Batisse D, Colin-de-Verdiere N et al.; Acute hepatitis C collaborating group. Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004. Euro Surveill. 10(5), 115-117 (2005).
17. Van De Laar Tj, Matthews Gv, Prins M, Danta M. Acute hepatitis C in HIVinfected men who have sex with men: An emerging sexually transmitted infection. Aids 24(12), 1799-1812 (2010).
18. Pappalardo BL. Influence of maternal human immunodeficiency virus (HIV) co-infection on vertical transmission of hepatitis C virus (HCV): A meta-analysis. Int. J. Epidemiol. 32(5), 727-734 (2003). (Pubitemid 37304630)
19. Thomson EC, Fleming VM, Main J et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut 60(6), 837-845 (2011).
20. Bourcier V, Winnock M, Ait Ahmed M et al.; for the ANRS CO13 Hepavih, ANRS CO12 Cirvir study groups. Primary liver cancer is more aggressive in HIVHCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir). Clin. Res. Hepatol. Gastroenterol. 36(3), 214-221 (2011).
21. Rosenthal E, Salmon-Céron D, Lewden C et al.; Mortavic/ Mortalité 2005 Study Group. Liver-related deaths in HIVinfected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalité 2005 survey, ANRS EN19). HIV Med. 10(5), 282-289 (2009).
22. Migueles SA, Laborico AC, Shupert WL et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 3(11), 1061-1068 (2002). (Pubitemid 35363659)
23. Ferre AL, Hunt PW, Critchfield JW et al. Mucosal immune responses to HIV-1 in elite controllers: A potential correlate of immune control. Blood 113(17), 3978-3989 (2009).
24. Sáez-Cirión A, Lacabaratz C, Lambotte O et al.; Agence Nationale de Recherches sur le Sida EP36 HIV Controllers Study Group. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl Acad. Sci. USA 104(16), 6776-6781 (2007). (Pubitemid 47175577)
25. Lambotte O, Ferrari G, Moog C et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 23(8), 897-906 (2009).
26. Sajadi MM, Shakeri N, Talwani R, Redfield RR. Hepatitis C infection in HIV-1 natural viral suppressors. AIDS 24(11), 1689-1695 (2010).
27. Ruiz-Mateos E, Machmach K, Romero-Sanchez MC et al.; Cohort of the Spanish AIDS Research Network. Hepatitis C virus replication in Caucasian HIV controllers. J. Viral Hepat. 18(7), e350-e357 (2011).
28. Alatrakchi N, Di Martino V, Thibault V, Autran B; ALT and IMMUNE-VIRC ANRS study groups. Strong CD4 Th1 responses to HIV and hepatitis C virus in HIV-infected long-term non-progressors co-infected with hepatitis C virus. AIDS 16(5), 713-717 (2002). (Pubitemid 34274461)
29. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: A tale of coevolution and coexistence. J. Clin. Invest. 119(7), 1745-1754 (2009).
30. Diepolder HM, Zachoval R, Hoffmann RM et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346(8981), 1006-1007 (1995).
31. Missale G, Bertoni R, Lamonaca V et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J. Clin. Invest. 98(3), 706-714 (1996). (Pubitemid 26349175)
32. Kaplan DE, Sugimoto K, Newton K et al. Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology 132(2), 654-666 (2007). (Pubitemid 46274664)
33. Urbani S, Amadei B, Fisicaro P et al. Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Hepatology 44(1), 126-139 (2006). (Pubitemid 44049146)
34. Gerlach JT, Diepolder HM, Jung MC et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 117(4), 933-941 (1999). (Pubitemid 29468237)
35. Lechner F, Wong DK, Dunbar PR et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191(9), 1499-1512 (2000). (Pubitemid 30257347)
36. Grakoui A, Shoukry NH, Woollard DJ et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 302(5645), 659-662 (2003). (Pubitemid 37310924)
37. Thimme R, Bukh J, Spangenberg HC et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc. Natl Acad. Sci. USA 99(24), 15661-15668 (2002). (Pubitemid 35403988)
38. Pestka JM, Zeisel MB, Bläser E et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl Acad. Sci. USA 104(14), 6025-6030 (2007). (Pubitemid 47175652)
39. Lavillette D, Morice Y, Germanidis G et al. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J. Virol. 79(10), 6023-6034 (2005). (Pubitemid 40617208)
40. Farci P, Alter HJ, Wong DC et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc. Natl Acad. Sci. USA 91(16), 7792-7796 (1994).
41. Farci P, Shimoda A, Wong D et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc. Natl Acad. Sci. USA 93(26), 15394-15399 (1996). (Pubitemid 27009611)
42. Takaki A, Wiese M, Maertens G et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat. Med. 6(5), 578-582 (2000). (Pubitemid 30305910)
43. Shoukry NH, Grakoui A, Houghton M et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J. Exp. Med. 197(12), 1645-1655 (2003). (Pubitemid 36745340)
44. Lai ME, Mazzoleni AP, Argiolu F et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 343(8894), 388-390 (1994). (Pubitemid 24049557)
45. Asselah T, Vidaud D, Doloy A et al. Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy. Gut 52(6), 900-902 (2003). (Pubitemid 36613501)
46. Gerlach JT, Diepolder HM, Zachoval R et al. Acute hepatitis C: High rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 125(1), 80-88 (2003). (Pubitemid 36799109)
47. Grebely J, Conway B, Raffa JD, Lai C, Krajden M, Tyndall MW. Hepatitis C virus reinfection in injection drug users. Hepatology 44(5), 1139-1145 (2006). (Pubitemid 44748365)
48. Osburn WO, Fisher BE, Dowd KA et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 138(1), 315-324 (2010).
49. Barth H, Rybczynska J, Patient R et al. Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees. Hepatology 54(4), 1135-1148 (2011).
50. Bukh J, Thimme R, Meunier JC et al. Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J. Virol. 82(16), 8183-8195 (2008).
51. Crispe IN. Hepatic T cells and liver tolerance. Nat. Rev. Immunol. 3(1), 51-62 (2003). (Pubitemid 37328699)
52. McKiernan SM, Hagan R, Curry M et al. Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology 40(1), 108-114 (2004). (Pubitemid 38877575)
53. Thursz M, Yallop R, Goldin R, Trepo C, Thomas HC. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet 354(9196), 2119-2124 (1999). (Pubitemid 30008896)
54. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262), 399-401 (2009).
55. Thomas DL, Thio CL, Martin MP et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461(7265), 798-801 (2009).
56. Watanabe H, Saito T, Shinzawa H et al. Spontaneous elimination of serum hepatitis C virus (HCV) RNA in chronic HCV carriers: A population-based cohort study. J. Med. Virol. 71(1), 56-61 (2003). (Pubitemid 37121913)
57. Cacopardo B, Nunnari G, Nigro L. Clearance of HCV RNA following acute hepatitis A superinfection. Dig. Liver Dis. 41(5), 371-374 (2009).
58. Jessner W, Strasser M, Graziadei I, Berr F, Vogel W. Sustained remission of chronic hepatitis C after acute hepatitis B superinfection. Scand. J. Infect. Dis. 38(9), 818-821 (2006). (Pubitemid 44304977)
59. Gruener NH, Jung MC, Ulsenheimer A et al. Hepatitis C virus eradication associated with hepatitis B virus superinfection and development of a hepatitis B virus specific T cell response. J. Hepatol. 37(6), 866-869 (2002). (Pubitemid 35404229)
60. Deterding K, Pothakamuri SV, Schlaphoff V et al. Clearance of chronic HCV infection during acute delta hepatitis. Infection 37(2), 159-162 (2009).
61. Welsh RM, Selin LK. No one is naive: The significance of heterologous T-cell immunity. Nat. Rev. Immunol. 2(6), 417-426 (2002). (Pubitemid 37328749)
62. Raghuraman S, Park H, Osburn WO, Winkelstein E, Edlin BR, Rehermann B. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J. Infect. Dis. 205(5), 763-771 (2012).
63. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 434(7037), 1093-1097 (2005). (Pubitemid 40663481)
64. Li Q, Duan L, Estes JD et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 434(7037), 1148-1152 (2005). (Pubitemid 40663495)
65. Lauer GM, Ouchi K, Chung RT et al. Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J. Virol. 76(12), 6104-6113 (2002). (Pubitemid 34556305)
66. Valdez H, Anthony D, Farukhi F et al. Immune responses to hepatitis C and non-hepatitis C antigens in hepatitis C virus infected and HIV-1 coinfected patients. AIDS 14(15), 2239-2246 (2000).
67. Graham CS, Wells A, Liu T et al.; ACTG 5071 Study Team. Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection. AIDS 19(8), 767-773 (2005). (Pubitemid 40834746)
68. Dutoit V, Ciuffreda D, Comte D, Gonvers JJ, Pantaleo G. Differences in HCV-specific T cell responses between chronic HCV infection and HIV/HCV co-infection. Eur. J. Immunol. 35(12), 3493-3504 (2005). (Pubitemid 43025531)
69. Harcourt G, Gomperts E, Donfield S, Klenerman P. Diminished frequency of hepatitis C virus specific interferon gamma secreting CD4+ T cells in human immunodeficiency virus/hepatitis C virus coinfected patients. Gut 55(10), 1484-1487 (2006). (Pubitemid 44476795)
70. Canchis PW, Yee HT, Fiel MI et al. Intrahepatic CD4+ cell depletion in hepatitis C virus/HIV-coinfected patients. J. Acquir. Immune Defic. Syndr. 37(1), 1125-1131 (2004). (Pubitemid 39166646)
71. Graham CS, Curry M, He Q et al. Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV. Hepatology 40(1), 125-132 (2004). (Pubitemid 38868931)
72. Kim AY, Lauer GM, Ouchi K et al. The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1. Blood 105(3), 1170-1178 (2005). (Pubitemid 40170890)
73. Kim AY, Schulze zur Wiesch J, Kuntzen T et al. Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection. PLoS Med. 3(12), e492 (2006).
74. Rohrbach J, Robinson N, Harcourt G et al.; Swiss HIV Cohort Study. Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut 59(9), 1252-1258 (2010).
75. Lambotin M, Raghuraman S, Stoll-Keller F, Baumert TF, Barth H. A look behind closed doors: Interaction of persistent viruses with dendritic cells. Nat. Rev. Microbiol. 8(5), 350-360 (2010).
76. Brown BL, Grigoriu S, Kim Y et al. Three dimensional structure of the MqsR:MqsA complex: A novel TA pair comprised of a toxin homologous to RelE and an antitoxin with unique properties. PLoS Pathog. 5(12), e1000706 (2009).
77. Boasso A, Shearer GM. Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin. Immunol. 126(3), 235-242 (2008). (Pubitemid 351221427)
78. Altfeld M, Fadda L, Frleta D, Bhardwaj N. DCs and NK cells: Critical effectors in the immune response to HIV-1. Nat. Rev. Immunol. 11(3), 176-186 (2011).
79. Cheent K, Khakoo SI. Natural killer cells and hepatitis C: Action and reaction. Gut 60(2), 268-278 (2011).
80. Moir S, Fauci AS. B cells in HIV infection and disease. Nat. Rev. Immunol. 9(4), 235-245 (2009).
81. Jang JY, Shao RX, Lin W et al. HIV infection increases HCV-induced hepatocyte apoptosis. J. Hepatol. 54(4), 612-620 (2011).
82. Lin W, Weinberg EM, Tai AW et al. HIV increases HCV replication in a TGF-beta1-dependent manner. Gastroenterology 134(3), 803-811 (2008). (Pubitemid 351312737)
83. Thompson MA, Aberg JA, Cahn P et al.; International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304(3), 321-333 (2010).
84. Seden K, Back D, Khoo S. New directly acting antivirals for hepatitis C: Potential for interaction with antiretrovirals. J. Antimicrob. Chemother. 65(6), 1079-1085 (2010).
85. Laguno M, Murillas J, Blanco JL et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 18(13), F27-F36 (2004). (Pubitemid 39179626)
86. Arizcorreta A, Márquez M, Fernández-Gutiérrez C et al. T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: Analysis in a population on effective antiretroviral therapy. Clin. Exp. Immunol. 146(2), 270-277 (2006). (Pubitemid 44581342)
87. Neukam K, Camacho A, Caruz A et al. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. J. Hepatol. 56(4), 788-794 (2012).
88. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41(10), 1105-1109 (2009).
89. Dayyeh BK, Gupta N, Sherman KE, de Bakker PI, Chung RT; Aids Clinical Trials Group A5178 Study Team. IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy. PLoS ONE 6(10), e25753 (2011).
90. Rallón NI, Naggie S, Benito JM et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 24(8), F23-F29 (2010).
91. Sherman KE, Thomas DL, Chung RT. Human immunodeficiency virus and liver disease forum 2010: Conference proceedings. Hepatology 54(6), 2245-2253 (2011).
92. Sulkowski MS. Hepatitis C virus-human immunodeficiency virus coinfection. Liver Int. 32(Suppl. 1), 129-134 (2012).
93. Soriano V, Sherman KE, Rockstroh J et al. Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients. AIDS 25(18), 2197-2208 (2011).
94. Houghton M. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol. Rev. 239(1), 99-108 (2011).
95. Folgori A, Capone S, Ruggeri L et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat. Med. 12(2), 190-197 (2006). (Pubitemid 43214745)
96. Barnes E, Folgori A, Capone S et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci. Transl. Med. 4(115), 115ra1 (2012).
97. Choo QL, Kuo G, Ralston R et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl Acad. Sci. USA 91(4), 1294-1298 (1994). (Pubitemid 24058997)
98. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 436(7053), 961-966 (2005). (Pubitemid 41191672)
99. Stamataki Z, Coates S, Evans MJ et al. Hepatitis C virus envelope glycoprotein immunization of rodents elicits crossreactive neutralizing antibodies. Vaccine 25(45), 7773-7784 (2007). (Pubitemid 47588528)
100. Stoll-Keller F, Barth H, Fafi-Kremer S, Zeisel MB, Baumert TF. Development of hepatitis C virus vaccines: Challenges and progress. Expert Rev. Vaccines 8(3), 333-345 (2009).
101. Halliday J, Klenerman P, Barnes E. Vaccination for hepatitis C virus: Closing in on an evasive target. Expert Rev. Vaccines 10(5), 659-672 (2011).
102. Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J. Hepatol. 54(6), 1273-1285 (2011).
103. Strickland GT, El-Kamary SS, Klenerman P, Nicosia A. Hepatitis C vaccine: Supply and demand. Lancet Infect. Dis. 8(6), 379-386 (2008). (Pubitemid 351697805)
104. Frey SE, Houghton M, Coates S et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 28(38), 6367-6373 (2010).
105. Ray A, Marshall V, Uldrick T et al. Sequence analysis of kaposi sarcoma-associated herpesvirus (KSHV) microRNAs in patients with multicentric castleman disease and KSHV-associated inflammatory cytokine syndrome. J. Infect. Dis. 205(11), 1665-1676 (2012).
106. Drane D, Maraskovsky E, Gibson R et al. Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: A Phase I study in healthy volunteers. Hum. Vaccin. 5(3), 151-157 (2009).
107. Garrone P, Fluckiger AC, Mangeot PE et al. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci. Transl. Med. 3(94), 94ra71 (2011).
108. Habersetzer F, Honnet G, Bain C et al. A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology 141(3), 890-899.e1, (2011).
109. Klade CS, Wedemeyer H, Berg T et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 134(5), 1385-1395 (2008).
110. Sallberg MM, Frelin L, Diepolder H et al. 43 A first clinical trial of therapeutic vaccination using naked dna delivered by in vivo electroporation shows antiviral effects in patients with chronic hepatitis C. J. Hepatol. 50(Suppl. 1), S18-S19 (2009).
111. Alvarez-Lajonchere L, Shoukry NH, Grá B et al. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial. J. Viral Hepat. 16(3), 156-167 (2009).
112. Habersetzer F, Baumert TF, Stoll-Keller F. GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection. Curr. Opin. Mol. Ther. 11(4), 456-462 (2009).
113. Schiff E, Everson Gt, Tsai N et al. HCV-specific cellular immunity, RNA reductions, and normalization of ALT in chronic HCV subjects after treatment with GI-5005, a yeast-based immunotherapy targeting NS3 and core: A randomized, double-blind, placebo controlled Phase 1B study. Hepatology 46(4), 816A (2007).
114. Wedemeyer H, Janczewska-Kazek, E, Mazur WW et al. HCVAC study: Antiviral activity of TG4040 therapeutic vaccine in genotype-1 chronic HCV patients. Hepatology 54(4 Suppl. 1), 989A (2011).
115. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: A review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect. Dis. 9(8), 493-504 (2009).
116. Kim HN, Harrington RD, Crane HM, Dhanireddy S, Dellit TH, Spach DH. Hepatitis B vaccination in HIV-infected adults: Current evidence, recommendations and practical considerations. Int. J. STD AIDS 20(9), 595-600 (2009).
117. Bongiovanni M, Casana M. Hepatitis B vaccination in HIV-infected subjects. Curr. Mol. Pharmacol. 1(3), 191-194 (2008).
118. Nosyk B, Sharif B, Sun H, Cooper C, Anis AH; CIHR Canadian HIV Trials Network Influenza Vaccine Research Group. The cost-effectiveness and value of information of three influenza vaccination dosing strategies for individuals with human immunodeficiency virus. PLoS ONE 6(12), e27059 (2011).
119. Laurence JC. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am. J. Med. 118(Suppl. 10A), 75S-83S (2005). (Pubitemid 41552437)
120. Yamanaka H, Teruya K, Tanaka M et al.; HIV/Influenza Vaccine Study Team. Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. 39(2), 167-173 (2005). (Pubitemid 40741114)
121. Horster S, Laubender RP, Lehmeyer L et al. Influence of antiretroviral therapy on immunogenicity of simultaneous vaccinations against influenza, pneumococcal disease and hepatitis A and B in human immunodeficiency virus positive individuals. J. Infect. 61(6), 484-491 (2010).
122. Agrati C, Gioia C, Castilletti C et al. Cellular and humoral immune responses to pandemic influenza vaccine in healthy and in highly active antiretroviral therapy-treated HIV patients. AIDS Res. Hum. Retroviruses doi:10.1089/ aid.2011.0371 (2012) (Epub ahead of print).
123. Psevdos G, Kim JH, Groce V, Sharp V. Efficacy of double-dose hepatitis B rescue vaccination in HIV-infected patients. AIDS Patient Care STDS 24(7), 403-407 (2010).
124. Anema A, Mills E, Montaner J, Brownstein JS, Cooper C. Efficacy of influenza vaccination in HIV-positive patients: A systematic review and meta-analysis. HIV Med. 9(1), 57-61 (2008).
125. Moir S, Ho J, Malaspina A et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J. Exp. Med. 205(8), 1797-1805 (2008).
126. Moir S, Chun TW, Fauci AS. Pathogenic mechanisms of HIV disease. Annu. Rev. Pathol. 6, 223-248 (2011). Addresses advancements in the understanding of the pathogenic mechanisms of HIV disease.
127. Moir S, Malaspina A, Ho J et al. Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. J. Infect. Dis. 197(4), 572-579 (2008). (Pubitemid 351321535)
128. Hadigan C, Kottilil S. Hepatitis C virus infection and coinfection with human immunodeficiency virus: Challenges and advancements in management. JAMA 306(3), 294-301 (2011).
129. Operskalski EA, Kovacs A. HIV/HCV co-infection: Pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr. HIV/AIDS Rep. 8(1), 12-22 (2011).
130. Gaucher D, Therrien R, Kettaf N et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J. Exp. Med. 205(13), 3119-3131 (2008).
131. Nakaya HI, Wrammert J, Lee EK et al. Systems biology of vaccination for seasonal influenza in humans. Nat. Immunol. 12(8), 786-795 (2011).
132. Nakaya HI, Pulendran B. Systems vaccinology: Its promise and challenge for HIV vaccine development. Curr. Opin. HIV AIDS 7(1), 24-31 (2012).